Lepirudin

Also known as: Hirudin, Desirudin

Drug #1669

Lepirudin is a recombinant hirudin which is used as anticoaggulant in patients with heparin-induced thrombocytopenia who require parenteral antithrombotic treatment. Lepirudin is being invastigated in arterial thrombo-embolic disorders such as angina and MI (myocardial infarction).

← Previous drug Next drug →

Primary Characteristics

Lepirudin is also known as Hirudin, Desirudin.

It is of Semi Synthetic origin.

Molecular Weight: 6979.5 · Solubility in Water: Freely soluble · Non-proprietary name: Lepirudin · pH: 4.4.

Pharmacokinetics

Distribution: Lepirudin has a volume of distribution is 0.27 L/kg.

Elimination: it is metabolised via Hepatic, plasma half-life is 1-2 hr, renal excretion is 45% Urine.

Indications

Lepirudin is primarily indicated in conditions like Endometrial thinning before intra-uterine surgery.

Contraindications

Lepirudin is contraindicated in conditions like Pregnancy, Breast feeding.

Dosage

Lepirudin's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
150 mcg/kg of body weight	150 mcg/kg of body weight	—	IV	Followed after initial dose
400 mcg/kg of body weight	400 mcg/kg of body weight	—	IV	Initial
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Lepirudin in overdosage may give rise to further complications which include Bleeding , Hematoma, Hematoma, Hypersensitivity.

Lepirudin produces potentially life-threatening effects which include Intracranial hemorrhages. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Lepirudin are Bleeding complications.

Lepirudin is known to cause more or less tolerable side effects which are usually transient. These include Allergic reactions, Anemia, Fever, Hematuria, Rectal bleeding.

Warnings / Precautions

Renal impairment; hepatic impairment; recent bleeding or risk of bleeding including recent puncture of large vessels, organ biopsy, recent major surgery, stroke, haemorrhagic diathesis, severe uncontrolled hypertension, bacterial endocarditis; determine activated partial thromboplastin time 4 hrs after start of treatment (or after infusion rate altered) and at least once daily thereafter.

Available Brands

None recorded.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators